Get the Stockscreener App
148.14
1.04%
-1.56
After Hours:
148.38
0.24
+0.16%
Insulet Corp stock is traded at $148.14, with a volume of 1.04M.
It is down -1.04% in the last 24 hours and up +0.46% over the past month.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.
See More
Previous Close:
$149.70
Open:
$149.23
24h Volume:
1.04M
Relative Volume:
0.79
Market Cap:
$10.26B
Revenue:
$2.90B
Net Income/Loss:
$302.80M
P/E Ratio:
34.48
EPS:
4.2965
Net Cash Flow:
$387.80M
1W Performance:
-2.22%
1M Performance:
+0.46%
6M Performance:
-49.18%
1Y Performance:
-51.37%
1-Day Range:
$147.46
$150.58
1-Week Range:
$145.14
$161.35
52-Week Range:
$140.63
$354.88
Insulet Corp Stock (PODD) Company Profile
Name
Insulet Corp
Sector
Industry
Phone
978-600-7000
Address
100 NAGOG PARK, ACTON, MA
Compare PODD vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PODD
Insulet Corp
|
148.14 | 10.37B | 2.90B | 302.80M | 387.80M | 4.2965 |
ABT
Abbott Laboratories
|
88.67 | 153.59B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
307.94 | 119.69B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
80.38 | 102.97B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
46.76 | 69.72B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.28 | 49.01B | 6.30B | 1.07B | 1.09B | 1.8406 |
Insulet Corp Stock (PODD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-24-26 | Downgrade | Rothschild & Co Redburn | Buy → Neutral |
| Apr-07-26 | Downgrade | Citigroup | Buy → Neutral |
| Jan-27-26 | Resumed | TD Cowen | Hold |
| Jan-12-26 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-16-25 | Initiated | Evercore ISI | Outperform |
| Nov-19-25 | Upgrade | UBS | Neutral → Buy |
| Oct-21-25 | Resumed | Stifel | Buy |
| Sep-08-25 | Resumed | Oppenheimer | Outperform |
| Jun-16-25 | Initiated | Truist | Buy |
| May-30-25 | Initiated | Goldman | Buy |
| May-13-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Apr-29-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Mar-06-25 | Initiated | RBC Capital Mkts | Outperform |
| Nov-06-24 | Initiated | Bernstein | Outperform |
| May-30-24 | Initiated | Redburn Atlantic | Buy |
| May-07-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-21-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-04-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-02-23 | Upgrade | Jefferies | Hold → Buy |
| Aug-21-23 | Upgrade | Citigroup | Neutral → Buy |
| Aug-21-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-26-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-04-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-18-22 | Initiated | Barclays | Equal Weight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-11-22 | Downgrade | Citigroup | Buy → Neutral |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Feb-03-22 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-02-22 | Upgrade | UBS | Neutral → Buy |
| Jan-31-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-01-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-19-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Jan-29-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Jul-28-20 | Initiated | Wells Fargo | Overweight |
| Apr-24-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-03-20 | Initiated | BofA/Merrill | Neutral |
| Mar-31-20 | Downgrade | Berenberg | Buy → Hold |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Dec-10-19 | Initiated | CFRA | Sell |
| Oct-23-19 | Initiated | Stifel | Hold |
| Oct-18-19 | Downgrade | Canaccord Genuity | Buy → Hold |
| Oct-14-19 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-04-19 | Downgrade | UBS | Buy → Neutral |
| Oct-03-19 | Downgrade | Guggenheim | Buy → Neutral |
| Aug-06-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-10-19 | Downgrade | Northland Capital | Outperform → Market Perform |
| May-06-19 | Upgrade | BTIG Research | Neutral → Buy |
| Apr-20-18 | Initiated | Berenberg | Buy |
| Feb-22-18 | Reiterated | Barclays | Overweight |
| Jan-08-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Nov-03-17 | Upgrade | Canaccord Genuity | Hold → Buy |
| Sep-15-17 | Initiated | Barclays | Overweight |
View All
Insulet Corp Stock (PODD) Latest News
Insulet Stock (US45784P1012): Ownership Changes Put Diabetes Tech Group in Focus - AD HOC NEWS
Insulet Corp. stock outperforms competitors on strong trading day - MSN
Top medtech stories from ADA’s Scientific Sessions - MedTech Dive
Why is Insulet (PODD) down 8.7% since last earnings report? - MSN
Insulet Corp. stock underperforms Thursday when compared to competitors - MarketWatch
Insulet Corp. stock underperforms Wednesday when compared to competitors - MSN
Is Insulet Corporation (PODD) A Good Stock To Buy Now? - Yahoo Finance
Truist cuts Insulet stock price target to $219 on valuation - Investing.com
Assessing Insulet (PODD) Valuation After New Omnipod Clinical Data And System Updates - Yahoo Finance
Insulet Corporation $PODD Shares Sold by Allianz Asset Management GmbH - MarketBeat
Insulet Corp (PODD) Shares Surge 5.3% -- What GF Score of 82 Tel - GuruFocus
Insulet Independent Chair Acquires 66% More Stock - Moomoo
Insulet reports new data for Omnipod 6 and FCL systems - MSN
Insulet Corp. stock underperforms Monday when compared to competitors - MarketWatch
Insulet (PODD) Enhances Omnipod 5 System with New Target Glucose Option - Insider Monkey
Insulet (PODD) Reveals Promising Advances in Automated Insulin D - GuruFocus
Prudential PLC Has $5.68 Million Stock Position in Insulet Corporation $PODD - MarketBeat
CIBC Asset Management Inc Purchases 6,821 Shares of Insulet Corporation $PODD - MarketBeat
5 Oversold Stocks to Buy Right Now - Insider Monkey
ETFs Investing in Insulet Corporation Stocks - TradingView
Soleus Capital Management, L.P.'s Insulet Corp(PODD) Holding History - GuruFocus
INSULET CORP (NASDAQ:PODD) Fits the Affordable Growth Mold with Strong Momentum and Reasonable Valuation - ChartMill
Insulet presents clinical trial data for diabetes devices - Investing.com
Insulin pump trials: Omnipod 6 lifts time in range with fewer boluses - Stock Titan
Insulet Reveals New Data Supporting Breakthrough Omnipod® 6 and Fully Closed-Loop AID Systems Designed to Improve Outcomes, Reduce Effort, and Unlock Barriers to Care - Yahoo Finance
Earnings call transcript: Insulet’s Q1 2026 earnings beat expectations, stock dips - Investing.com
Insulet shares surge 9% on strong earnings beat - Investing.com
Federal Circuit Overturns $59 Million Trade Secret Award Against EOFlow In Statute Of Limitations Ruling - londoninsider.co.uk
Insulet shares rise as investors focus on Omnipod 5 software upgrade and expanded CGM compatibility - Quiver Quantitative
Moody’s revises Insulet outlook on product recall concerns - Investing.com
PODD Stock Balances Device Setback With Omnipod Upgrade Momentum - StocksToTrade
Why Is Insulet (PODD) Down 8.7% Since Last Earnings Report? - Yahoo Finance
Divided Federal Circuit Panel Nixes $452 Million Trade Secret Judgment as Time-Barred - Holland & Knight
Dexcom buys Nutrisense; Insulet rolls out patch pump update - Yahoo Finance
Is Omnipod 5’s Algorithm and Libre 3 Plus Upgrade Altering The Investment Case For Insulet (PODD)? - Yahoo Finance
Insulet Q1 2026 slides: 34% revenue growth amid stock decline - Investing.com
Insider Buying: Timothy Stonesifer Acquires Shares of Insulet Co - GuruFocus
Insulet Corp director Luciana Borio sells $59,886 in stock - Investing.com UK
Insulet Corp director Luciana Borio sells $59,886 in stock By Investing.com - Investing.com Australia
Insulet Corp director Timothy Stonesifer acquires $400,392 in stock By Investing.com - Investing.com India
Insulet Corp. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Insulet Corp director Timothy Stonesifer acquires $400,392 in stock - Investing.com
[Form 4] INSULET CORP Insider Trading Activity - Stock Titan
Insulet (NASDAQ: PODD) director sells 418 shares in open-market trade - Stock Titan
Insulet director Elizabeth Weatherman buys $497k in shares By Investing.com - Investing.com India
Insulet (PODD) Alerts Customers About Omnipod Pod Safety Concern - GuruFocus
Insulet (PODD) Outlines Plans for ADA 2026 Presentation - GuruFocus
DexCom vs. Insulet: Which Diabetes Stock Is a Better Buy in 2026? - The Motley Fool
3 Reasons We’re Fans of Insulet (PODD) - Yahoo Finance
Why is Insulet stock rallying today? - Investing.com
Why is Insulet stock rallying today? By Investing.com - Investing.com India
Insulet Corp Stock (PODD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):